secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001104659-23-039554
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma reports FY2022 net loss $39.8M; advances NRX-101 trials, issues going concern warning
--------------------------------------------------------------------------------

- Net loss $39.8M for FY2022 vs $93.1M prior year; R&D $17.0M, G&A $27.4M.
- Cash $20.1M at Dec 31, 2022; raised $2.9M in March 2023 registered direct offering.
- DSMB cleared NRX-101 Phase 2b/3 trial for suicidal treatment-resistant bipolar depression; topline data expected 4Q2023.
- FDA suggested broader outpatient indication for NRX-101; safety database of 1,500 patients required.
- Going concern doubt: no revenue, $11M note to Streeterville Capital may require cash repayment; additional financing needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/0001104659-23-039554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/tm2311032d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer